2002 in cancer

FDA · US: 29 records / 13 drugsEMA · EU: 2 records / 2 drugsHealth Canada · CA: 2 records / 2 drugs

• Jul 24, 2002Leuprolide FDA · US original application approved Malignant Prostate NeoplasmVABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of…openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated…openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated…openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy FASLODEX is indicated for…openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or…openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1)openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or…openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after…openfda
• Apr 25, 2002Fulvestrant FDA · US original application approved Malignant Breast NeoplasmHR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after…openfda
• Feb 19, 2002Ibritumomab Tiuxetan FDA · US original application approved B-Cell Non-Hodgkin Lymphomarelapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL)openfda
• Jan 23, 2002Leuprolide FDA · US original application approved Malignant Prostate NeoplasmVABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of…openfda
• Oct 16, 2002Peginterferon Alfa-2a FDA · US original application approved cancer not stated in this recordPEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) • Adult Patients: In combination therapy with…openfda
• Mar 7, 2002Interferon Beta-1a FDA · US original application approved cancer not stated in this recordREBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and…openfda
• Feb 19, 2002Ibritumomab Tiuxetan FDA · US original application approved cancer not stated in this record. previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapyopenfda
• Jan 31, 2002Pegfilgrastim FDA · US original application approved cancer not stated in this recordNeulasta is a leukocyte growth factor indicated in adult and pediatric patients to Decrease the incidence of infection, as manifested by febrile neutropenia,…openfda
• Mar 5, 2002Arsenic Trioxide EMA · EU centralised approved Acute Promyelocytic LeukemiaTrisenox is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic…ema
• Dec 3, 2002Peginterferon Alfa-2a FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-12-03 (see label)openfda
• Nov 27, 2002Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-11-27 (see label)openfda
• Nov 12, 2002Interferon Beta-1a FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-11-12 (see label)openfda
• Sep 24, 2002Fludarabine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as FLUDARA (DIN 02246226) under ATC L01BB05 FLUDARABINE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Sep 20, 2002Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-09-20 (see label)openfda
• Sep 20, 2002Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-09-20 (see label)openfda
• Sep 20, 2002Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-09-20 (see label)openfda
• Sep 20, 2002Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-09-20 (see label)openfda
• Sep 17, 2002Irbesartan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-09-17 (see label)openfda
• Sep 5, 2002Anastrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-09-05 (see label)openfda
• Aug 28, 2002Trastuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-08-28 (see label)openfda
• Aug 22, 2002Pegfilgrastim EMA · EU centralised approved cancer not stated in this recordReduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the…ema
• Jun 7, 2002Celecoxib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-06-07 (see label)openfda
• May 16, 2002Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-05-16 (see label)openfda
• May 16, 2002Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-05-16 (see label)openfda
• May 10, 2002Tretinoin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2002-05-10 (see label)openfda
• May 1, 2002Glatiramer Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as COPAXONE (DIN 02245619) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd

RegulatoryAll 2002 records with filters →

Studies

393

Interventional

355

Phase III

68

Industry-led

207

With posted results

24

Countries with sites

63

Published source: clinicaltrials · first_posted_date as posted